<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05791890</url>
  </required_header>
  <id_info>
    <org_study_id>GilteRInf 2022</org_study_id>
    <nct_id>NCT05791890</nct_id>
  </id_info>
  <brief_title>GilteRInf 2022 Study (Gilteritinib Related Infections)</brief_title>
  <acronym>GilteRInf</acronym>
  <official_title>Observational Study on the Incidence of Infections in Patients With Relapsed/Refractory FMS-like Tyrosine Kinase 3 Acute Myeloid Leukemia Treated With Gilteritinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rome Tor Vergata</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rome Tor Vergata</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is observational, retrospective-prospective, multicenter &quot;real-life&quot; study&#xD;
      involving 26 centers belonging to the SEIFEM group. The goal of this study is to obtain a&#xD;
      real-life experience in the management and outcome of infectious issues of patients with&#xD;
      relapsed/resistant acute myeloid leukemia who receive Gilteritinib therapy, given that recent&#xD;
      approval of this drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is observational, retrospective-prospective, multicenter &quot;real-life&quot; study.&#xD;
      Regarding the retrospective part, clinical data will be collected on all patients with acute&#xD;
      myeloid leukemia FLT3+ treated with Gilteritinib from when the drug was approved and marketed&#xD;
      in Italy (April 2, 2020) until April 30, 2022. Enrollment in the prospective cohort will have&#xD;
      an estimated duration of 24 months from the time of study approval. Patients enrolled in the&#xD;
      last month will be followed for six months from the date of enrollment to check for the&#xD;
      occurrence of any infections. For each case of a patient receiving salvage monotherapy with&#xD;
      Gilteritinib, a control patient with relapsed/refractory FLT3+ acute myeloid leukemia on&#xD;
      salvage chemotherapy should also be included.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 31, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>absolute infectious risk in patients treated with Gilteritinib, Infection events of grade 3 or more ( CTCAE v.5.0 )</measure>
    <time_frame>24 months</time_frame>
    <description>To assess &quot;real-life&quot; in patients with relapsed/refractory FLT3+ LMA treated with Gilteritinib the absolute infectious risk and compare it with relapsed/refractory patients receiving chemotherapy. The</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Patients who receive or have received Gilteritinib</arm_group_label>
    <description>the retrospective part, clinical data will be collected on all patients with LMA FLT3+ (ITD or TKD mutation) treated with Gilteritinib from when the drug was approved and marketed in Italy (April 2, 2020) until April 30, 2022. Enrollment in the prospective cohort will have an estimated duration of 24 months from the time of study approval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Case control</arm_group_label>
    <description>for each case of a patient receiving salvage monotherapy with Gilteritinib, a control patient with R/R AML FLT3+ on salvage chemotherapy should also be included.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gilteritinib</intervention_name>
    <description>observational study to evaluate the incidence of infections during therapy with Gilteritinb</description>
    <arm_group_label>Case control</arm_group_label>
    <arm_group_label>Patients who receive or have received Gilteritinib</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Relapsed/refractory AML patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Population&#xD;
&#xD;
          -  All patients with FLT3+ relapsed/refractory AML to any line of therapy treated with&#xD;
             Gilteritinib&#xD;
&#xD;
          -  Patients â‰¥18 years of age&#xD;
&#xD;
          -  Signature of appropriate informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - Patients &lt; 18 years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Ilaria Del Principe, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rome Tor Vergata</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maria Ilaria Del Principe</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 5, 2023</study_first_submitted>
  <study_first_submitted_qc>March 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2023</study_first_posted>
  <last_update_submitted>March 17, 2023</last_update_submitted>
  <last_update_submitted_qc>March 17, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rome Tor Vergata</investigator_affiliation>
    <investigator_full_name>Maria Ilaria Del Principe</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>relapsed/refractory acute myeloid leukemia</keyword>
  <keyword>FLT3+</keyword>
  <keyword>FLT3 inhibitors</keyword>
  <keyword>Gilteritinib</keyword>
  <keyword>infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 14, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT05791890/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

